{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-21-134464","form_type":"8-K","ticker":"CYRX","cik":"0001124524","company_name":"Cryoport, Inc.","filed_at":"2021-11-04T23:59:59+00:00","discovered_at":"2026-05-14T18:04:11.571004+00:00","generated_at":"2026-06-28T12:35:47.818463+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Cryoport Q3 revenue $56.7M (+407% YoY); net loss $0.18/share; 582 clinical trials supported","bullets":["Total revenue $56.7M for Q3 2021, up 407% YoY; organic growth 38%.","Net loss attributable to common stockholders $8.5M ($0.18 per share), vs $11.4M ($0.29) in Q3 2020.","Adjusted EBITDA $5.6M in Q3 2021, vs -$0.7M in Q3 2020; gross margin 41.5% vs 54.2%.","Supported 582 clinical trials (up from 561 in Q2 2021) and eight commercial therapies in regenerative medicine.","Cash and short-term investments $349.5M as of Sep 30, 2021, up from $93.3M on Dec 31, 2020."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-21-134464","json":"https://secwatch.observer/filing/0001104659-21-134464.json","markdown":"https://secwatch.observer/filing/0001104659-21-134464.md","text":"https://secwatch.observer/filing/0001104659-21-134464.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1124524/000110465921134464/0001104659-21-134464-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1124524/000110465921134464/tm2126235d2_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-28T12:35:47.818463+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}